Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
The stuff touted to confer anti-aging properties on foods from blueberries to dark chocolate does no good for people with Alzheimer’s disease—and might even make them worse...
587 RESULTS
Sort By:
The stuff touted to confer anti-aging properties on foods from blueberries to dark chocolate does no good for people with Alzheimer’s disease—and might even make them worse...
Continued setbacks in Alzheimer’s disease clinical trials have fueled a sense that candidate drugs have been tested in patients whose disease has already progressed too far...
Move over Aβ and tau; it turns out that dozens of proteins rise and fall in the CSF of familial AD mutation carriers a decade before onset of the disease...
The longest study yet to correlate AD biomarkers in CSF with disease progression confirms that β amyloid levels bottom out up to 10 years before the clinical onset of disease...
Speakers wanted to bring frontotemporal degeneration (FTD) to the attention of the pharmaceutical industry and trialists working in Alzheimer’s disease...
New research boosts support for the use of magnetic resonance imaging (MRI) to identify seniors at the cusp of cognitive decline...
Scientists driving the Alzheimer's Prevention Initiative have been reporting at scientific conferences the first emerging biomarker findings from their human volunteers...
An excess of sirtuin one-ups mutant huntingtin in mice, saving neurons and delaying Huntington’s disease...
A popular model of Alzheimer’s disease progression proposes an ordered sequence by which the main biomarkers change...
Alzheimer’s disease researchers have puzzled over a strange surge of hippocampal firing in some seniors at the cusp of mental decline...
CTAD attendees got an earful about an arguably neglected topic in Alzheimer’s research, that is, the use of event-related potentials (ERP) as biomarkers of disease...
Regular visitors to Alzforum will be familiar with the use of PET, MRI, and cerebrospinal fluid measurements as markers for AD, But these are not the only AD biomarkers...
Researchers studying amyotrophic lateral sclerosis (ALS) have plenty of drug ideas to try, but a great problem in figuring out if they work or not...
Findings strengthen the case for using biomarkers to determine who is at risk for AD before symptoms develop...
ALS has joined the growing list of neurodegenerative diseases characterized by fluctuations in the amino acid N-acetylaspartate (NAA)—but with a twist...